Flucobay

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucobay

Flucobay is a prescription medicine containing the Fluconazole active compound, which is a cornerstone of antifungal therapy. It is classified as a specialized drug used for the control and management of systemic infections caused by various fungal organisms. It works by interfering with the integrity of the fungal cell structure, thereby halting the spread of the infection throughout the body.

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral Suspension, Intravenous (IV) Solution
Pharmacological Class Triazole Antifungal Agent
General Purpose Systemic control of fungal and yeast infections
Origin Synthetic Compound

What Type of Medicine is Flucobay?

Flucobay is a commercial name for the fully synthetic compound Fluconazole, which is classified as a systemic antifungal agent. Specifically, it belongs to the triazole class, an established group of antimycotic agents known for their efficacy against a broad range of fungal pathogens. Fluconazole is included on the list of Essential Medicines, signifying its importance in global health systems. As a single-ingredient product, its effect is attributed solely to the Fluconazole component, which is frequently used in scenarios requiring prolonged antifungal management.

Composition and Available Forms of Fluconazole

The medicine's composition is based on the Fluconazole active ingredient combined with specific excipients appropriate for its delivery method. Fluconazole is provided in several dosage forms and corresponding routes of administration, including tablets and capsules for oral ingestion, an oral suspension often favored for pediatric use, and a sterile intravenous solution. This versatility in forms is crucial for patient care, particularly because Fluconazole achieves excellent oral absorption, allowing for the flexible use of either the oral or intravenous route depending on the patient's need.

The Broad Antifungal Action of Flucobay

The fundamental purpose of Flucobay is to restrict the spread of fungal disease by exerting a primarily fungistatic effect on the invading organism. This function involves disrupting a critical metabolic process within the fungal cell. The drug works by inhibiting the activity of a fungal enzyme essential for producing ergosterol, the key component that maintains the stability and structure of the fungal cell membrane. By compromising this vital structure, Flucobay effectively neutralizes the pathogen's ability to grow and replicate, thereby aiding the body in resolving the underlying infection.

Regulatory References

  1. Essential Medicines
  2. NIH MedlinePlus Drug Information

What side effects are possible with Flucobay?

Possible Side Effects and Safety Information

The safety profile of Flucobay, which contains Fluconazole, is officially documented across several categories, ranging from common, expected events to rare, clinically significant adverse reactions. All documented effects are based on regulatory prescribing information.


Adverse Reactions by Frequency

The most frequent adverse events are generally gastrointestinal and neurological, as outlined in official regulatory documents:

  • Common (affecting 1 to 10 in 100 users): Headache, Nausea, Vomiting, Diarrhoea, Abdominal pain, and elevations in liver enzyme levels (e.g., ALT, AST).
  • Uncommon (affecting 1 to 10 in 1,000 users): Dizziness, Insomnia, Taste perversion, Constipation, Jaundice, and various skin rashes.
  • Rare (affecting 1 to 10 in 10,000 users): Serious events affecting major systems.

Serious Adverse Reactions

The official labeling documents rare but serious adverse reactions that necessitate caution and monitoring. These include severe Hepatic Toxicity (liver damage, which may lead to hepatic failure), serious skin disorders such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and Cardiovascular Events, specifically the risk of QT prolongation and Torsade de pointes (a type of heart rhythm disturbance).


Safety Considerations for Specific Populations

Official regulatory information addresses specific patient groups:

  • Hepatic and Renal Impairment: Caution is mandated for individuals with pre-existing liver or kidney dysfunction.
  • Pregnancy: Chronic high-dose use of Fluconazole during the first trimester is associated with a rare, specific pattern of congenital malformations, a risk explicitly detailed in official safety information.

Treatment must be immediately discontinued if signs of serious liver injury or a severe systemic rash develop, as per regulatory safety mandates.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Category Official Regulatory Documentation
Documented Presentations Hallucination and paranoid behavior are explicitly documented central nervous system (CNS) manifestations of overdosage. The potential for severe, life-threatening QT interval prolongation and Torsades de pointes is also a key risk factor cited in regulatory warnings.
Physiological Systems Overdosage primarily affects the CNS and the Cardiovascular System.
Urgent Help Required Immediate medical attention must be sought in all cases of suspected overdosage due to the risk of severe CNS and cardiac effects.

Mandated Supportive and Eliminative Measures

In the event of an overdosage, regulatory authorities mandate the immediate institution of symptomatic treatment coupled with supportive measures to stabilize the patient. Procedural intervention may be necessary to reduce high plasma concentrations. The official overdose profile states that gastric lavage should be considered if clinically indicated for the removal of unabsorbed drug. Because Fluconazole is largely excreted in the urine, hemodialysis is an established eliminative procedure. Regulatory documentation indicates that a three-hour session of hemodialysis decreases circulating fluconazole plasma levels by approximately 50%. All mandated emergency actions are focused on controlling the neurological and cardiovascular risks associated with high exposure.

Therapeutic Uses of Flucobay

Flucobay (Fluconazole) is commonly used to address the symptomatic burden and underlying cause of various fungal and yeast infections, offering targeted support across several key clinical domains. It is relevant in conditions marked by increased physiological stress due to fungal pathogens.


Key Therapeutic Applications and Benefits

Flucobay is commonly used in managing severe, deep-seated infections, including those where the fungus has spread into the bloodstream (candidemia) or reached the central nervous system as seen in cryptococcal meningitis. It is also applied in conditions presenting with localized, disruptive symptom manifestations of candidiasis, such as oral thrush, esophageal inflammation, and vaginal irritation. This provides support that helps ease the overall symptom burden, which contributes to easing the overall symptom load related to systemic imbalance like persistent fever and debilitating malaise, or intense localized burning and soreness.

An important therapeutic application is the use of Flucobay for prophylactic support, helping to reduce the incidence of serious fungal infections in immunocompromised patients or to help manage situations involving recurrent or episodic manifestations.

Quick Fact: Relief for Localized Irritation and Systemic Distress

This medication is applied in clinical settings that involve acute or unstable symptom patterns. “The medicine is applied in contexts where additional symptomatic support is needed, helping patients cope more steadily with difficult episodes and supporting general functional stability.”


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Flucobay

Flucobay (Fluconazole) is available for use across various populations, but its official regulatory labeling defines strict eligibility rules based on age, physiological status, and concurrent conditions.

Classification Populations and Conditions
Absolute Contraindication Patients with known hypersensitivity to fluconazole or other azole antifungals. Co-administration with drugs like Pimozide or Halofantrine is prohibited due to the risk of serious heart rhythm problems.
Restricted/Cautionary Use Hepatic or renal impairment requires use with caution and close monitoring. Patients with underlying cardiac conditions (e.g., arrhythmias, electrolyte imbalance) must use the medicine with caution.
Age-Related Status Adults are eligible for approved uses. Children are eligible for systemic infections, but use for certain localized infections (e.g., genital candidiasis) is not established. Older adults with reduced kidney function may require adjustment.
Physiological Restrictions Use during pregnancy is generally avoided unless the fungal infection is severe or life-threatening; prolonged or high-dose therapy is not recommended. Breastfeeding is not recommended after repeated or high doses.

Oral forms are also prohibited in patients with specific rare hereditary disorders, such as galactose intolerance or Lapp lactase deficiency.

What should I know about interactions with other medicines?

Flucobay (fluconazole) is a potent inhibitor of certain liver enzymes, primarily CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This enzyme inhibition can lead to increased blood levels of many co-administered medicines that are broken down by these pathways, increasing the risk of adverse effects.

Contraindicated Combinations

Co-administration with other medicines known to prolong the QT interval on the electrocardiogram and which are metabolized by CYP3A4 is strictly avoided. This includes specific medicines like cisapride, astemizole, erythromycin, pimozide, and quinidine, due to the potential for life-threatening heart rhythm issues.

Significant Interactions Requiring Monitoring

Due to the enzyme-inhibiting effect, caution and dosage adjustments are necessary with medicines that have a narrow therapeutic window. For example, co-administration with warfarin may increase the risk of bleeding, requiring frequent monitoring of coagulation tests. Plasma concentrations of immunosuppressants (e.g., cyclosporine, tacrolimus) and certain calcium channel blockers (e.g., nifedipine, amlodipine) are also increased, necessitating therapeutic monitoring and potential dose reduction. The effects of certain oral hypoglycemics (sulfonylureas) and antiepileptics like carbamazepine are also enhanced, requiring clinical attention.

Mechanism of Action

Inhibition of Fungal Ergosterol Biosynthesis

The core mechanism involves the drug's binding and inhibition of the fungal enzyme Lanosterol 14-alpha demethylase (CYP51). This action specifically halts a critical molecular step in the creation of ergosterol, the vital sterol component of the fungal cell membrane, thereby compromising the pathogen's structural regulation.

Structural Failure and Growth Containment

By preventing ergosterol formation, the mechanism leads to the accumulation of unstable 14alpha-methyl sterols and the creation of a fundamentally defective cell membrane in the fungus. This structural failure causes cellular leakage and increased permeability, which functionally limits the pathogen's growth and ability to replicate, establishing a fungistatic effect.

Mechanistic Limitations and Resistance

The effectiveness of this mechanism can be physiologically constrained in some fungal strains, primarily through the activation of efflux pump transporters that actively push the drug out of the cell, or through genetic alterations in the CYP51 target enzyme. These evasion mechanisms reduce the intracellular drug concentration below the inhibitory threshold, leading to reduced structural disruption.

Dosage and Administration Information

How Flucobay (Fluconazole) is Used

The usage of Flucobay is determined by official dosing guidelines that establish the required route, amount, and frequency of administration. The medicine is intended for systemic use and is available in forms for both oral ingestion (capsules, tablets, and suspension) and intravenous (IV) infusion. The daily dose amount remains consistent regardless of whether the oral or IV route is chosen.

Dosing Patterns and Frequency

Therapy often begins with a loading dose on the first day, equal to twice the subsequent maintenance dose, in order to quickly achieve required systemic levels. The standard maintenance dose for adults ranges from 50 mg to 400 mg and is typically taken once daily. In cases of uncomplicated candidiasis, a single oral dose of 150 mg is defined. Treatment can range from a short, single course to a long-term suppressive regimen lasting several months, such as in the prevention of Cryptococcal Meningitis relapse.

Administration Conditions and Adjustments

Oral forms of Flucobay may be administered with or without food. For the intravenous solution, the label specifies that it must be delivered as an infusion at a rate not exceeding 10 mL/ minute. Dosing adjustments are mandatory for certain populations; for adults with significantly reduced kidney function, the daily maintenance dose must be reduced by 50% after the initial loading dose. Pediatric dosing is calculated using a weight-based mg/ kg approach.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flucobay

Evidence for Use in Systemic and Invasive Fungal Infections

The clinical evaluation of Fluconazole, the active component of Flucobay, has included substantial research into its use for severe, deep-seated fungal infections. This includes conditions where the fungus has spread through the body, such as Candidemia and severe central nervous system infections like Cryptococcal Meningitis.

The research base for these conditions primarily includes Randomized Controlled Trials (RCTs) and systematic reviews, which are study designs that are relevant in exploring patient outcomes. In studies evaluating systemic infections, research examined endpoints such as overall survival rates and measurements of mycological eradication, which refers to clearing the fungus from the blood or tissues. The medicine was observed in studies focused on these acute, life-threatening conditions.

For both candidemia and cryptococcal meningitis, the evidence is derived from research conducted during periods of increased symptom activity where patients were critically ill. However, the data show patterns related to the specific type of Candida being studied; research indicates that certain non-albicans species may exhibit limited susceptibility. Furthermore, outcomes reflecting daily functioning or functional recovery following the resolution of candidemia are not fully established in the existing evidence base.

Evidence for Use in Localized and Mucosal Candidiasis

The research base for Fluconazole also includes studies relevant in trials assessing short-term or episodic symptom patterns in localized infections, such as Oropharyngeal, Esophageal, and Vulvovaginal Candidiasis. These studies often take the form of short-term RCTs or comparative trials.

Research monitored outcomes capturing phases of heightened symptom activity, including endpoints like clinical cure (resolution of signs and symptoms) and mycological cure (laboratory confirmation of fungus clearance). In these contexts, studies monitored how symptoms evolved in the observed populations, and reported outcomes included measurements related to inflammatory or irritative states. The medicine was observed in trials that looked at how quickly symptoms were reported to evolve over short time intervals, typically one to three weeks.

Frequently Asked Questions (FAQ)

Common questions about Flucobay (FAQ)


Q: Does Flucobay cause weight gain, according to regulatory documents?

A: Official regulatory documents list common and uncommon adverse events for Flucobay, and weight gain is not explicitly listed among these events. However, official information does sometimes list anorexia (loss of appetite) as an infrequent gastrointestinal adverse event.


Q: How quickly does Flucobay start to work?

A: According to the official product information, the active ingredient in Flucobay is rapidly and well absorbed into the body after an oral dose. Peak blood levels are typically reached within one to two hours after taking the medicine. For this reason, a loading dose is sometimes used on the first day to help achieve the required systemic drug levels quickly.


Q: What happens if I forget to take a dose of Flucobay?

A: Patient information derived from regulatory sources generally advises that if a dose is forgotten, the general advice in patient information is to take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, in this situation, the patient information suggests skipping the missed dose to prevent taking two doses too closely together.


Q: Does Flucobay interact with common pain relievers?

A: Official drug interaction information indicates that Flucobay can interact with certain non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen. This occurs because Flucobay can increase the amount of the pain reliever circulating in the body, which may necessitate medical monitoring when they are co-administered.


Q: Is it normal for Flucobay to cause mild fatigue?

A: Yes, fatigue is listed as an infrequent side effect in some regulatory safety documents. Infrequent means it was observed in clinical trials in less than 1% of patients. This information is based on the official adverse event reporting data.


Q: Does Flucobay show up on drug tests?

A: Fluconazole, the active component, is not generally included in the panel of substances screened by routine drug abuse tests. However, it has been noted in medical literature related to anti-doping due to its potential to interfere with the body's natural processes that break down steroid hormones, which could potentially impact certain specific drug testing protocols.


Q: How long does Flucobay typically stay in your system?

A: Official pharmacokinetic data shows that Flucobay has a relatively long elimination half-life of approximately 30 hours in adults with healthy kidney function. Based on this, it typically takes roughly 5 to 10 days for the drug to be almost fully eliminated from the system after the final dose has been taken.


Q: Can Flucobay interact with alcohol?

A: While regulatory sources do not typically describe a direct pharmacological interaction that affects how the drug is processed, both alcohol consumption and Flucobay can independently affect the liver. For this reason, official guidance notes that alcohol intake is often limited or avoided during treatment, which is intended to reduce the potential for hepatic adverse effects.


Q: Why is Flucobay a prescription-only medicine?

A: Flucobay is classified as a prescription-only medicine due to its potential risk profile. The drug carries warnings for serious side effects, including the possibility of severe liver toxicity and the risk of serious heart rhythm disturbances (known as QT prolongation). Medical oversight is required to manage these risks and ensure the appropriate use for systemic infections.


Q: Are there any documented cases of overdose with Flucobay?

A: Yes, regulatory documents describe that overdose has occurred and is characterized by symptoms such as hallucinations and paranoid behavior. The regulatory documents describe that management of an overdose typically involves supportive measures.


Q: Does Flucobay affect fertility?

A: There are no extensive studies available in humans to draw a definitive conclusion regarding the effects of Flucobay on female or male fertility. Animal studies have described some temporary effects on sperm count, and these were noted to reverse following the discontinuation of the medicine.


Q: Are there any specific warnings for individuals with a history of mental health conditions?

A: Official labeling lists certain central nervous system (CNS) effects, such as headache and dizziness, as common adverse events. Furthermore, the overdose information cautions about the potential for mental status changes, specifically hallucinations and paranoid behavior, which indicates the drug's effect on CNS function.


Q: Do official labels describe potential interactions with birth control pills?

A: Yes, official regulatory documents note that Flucobay can alter the blood concentrations of certain types of oral contraceptives. This effect is specifically noted for birth control pills that contain components such as levonorgestrel, and may require careful monitoring.


Q: Can I take Flucobay with vitamins or herbal supplements?

A: Flucobay is known to influence liver enzymes that break down many substances, leading to a complex profile of drug interactions. Because interactions with vitamins and herbal supplements are highly variable and not fully covered in general documentation, official patient information states that a healthcare professional should be informed of all products taken concurrently due to the potential for complex interactions.

How should Flucobay be stored and disposed of?

The storage and disposal of Flucobay (Fluconazole) are governed by specific regulatory guidelines to ensure product stability and safety.

Storage Requirements

Temperature and Handling:

Store the product at controlled room temperature, typically between 20 C and 25 C. The Intravenous Solution must not be refrigerated or frozen, and should be stored in the outer carton to protect it from light. Capsules and tablets must be protected from moisture.

Stability: The IV solution is designated for single use only; any remaining portion must be discarded immediately. Check the solution for particulate matter before use. All forms must be kept out of the sight and reach of children.

Disposal

Expired or unused Flucobay must not be thrown away in household trash or wastewater. Dispose of the product by returning it to a pharmacist or a recognized drug take-back program, in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucobay found in:

A-Z Index: